Prof. Francesco Buccisano
Born on August 5, 1969 in Rome, Italy. Associate Professor of Hematology at the Department of Biomedicine and Prevention, University of Rome "Tor Vergata". In charge of the “Molecular treatment of Acute Leukemia” Program and the Flow Cytometry section of the Hematology Laboratory.
National and international board activities: President of the Italian Society of Cytometric Cell Analysis (ISCCA) since May 2016. Member of the European LeukemiaNet Working Party for Minimal Residual Disease in leukemia and of the board of the European Society of Cytometric Cell Analysis (ESCCA). Secretary of the Acute Leukemia Working Party of the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA).
Line of research: Principal investigator of several clinical protocols in acute myeloid leukemia, myelodysplastic syndromes and immune thrombocytopenia. Development of innovative techniques of monitoring and analysis of minimal residual disease in acute myeloid leukemia and in other hematological malignancies (myeloma, acute lymphoid leukemia). Conventional and experimental treatment of acute myeloid leukemia. Diagnosis and experimental treatment of Immune Thrombocytopenia.
Memberships: Active member of the American Society of Hematology (ASH), of the Italian Society if Hematology (SIE) and of the Italian Society of Experimental Hematology (SIES).
Publications: More than 120 publications in peer-reviewed journals. Personal H-index 32 (at November 2020).
1 Schuurhuis GJ, Heuser M, Freeman S, Béné M-C, Buccisano F, Cloos J et al. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood 2018; : blood-2017-09-801498.
2 Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012. doi:10.1182/blood-2011-08-363291.
3 Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010; 116: 2295–2303.
4 Hanekamp D, Snel AN, Kelder A, Scholten WJ, Khan N, Metzner M et al. Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. Br J Haematol 2020. doi:10.1111/bjh.16594.
5 Buccisano F, Dillon R, Freeman SD, Venditti A. Role of minimal (measurable) residual disease assessment in older patients with acute myeloid leukemia. Cancers (Basel) 2018; 10. doi:10.3390/cancers10070215.
6 Buccisano F, Maurillo L, Schuurhuis GJ, Del Principe MI, Di Veroli A, Gurnari C et al. The emerging role of measurable residual disease detection in AML in morphologic remission. Semin Hematol 2019; 56: 125–130.